Table 4 Characteristics of patients with ABPA before and after receiving omalizumab

Blood eosinophil count, cells/µL

590 (270–840)

180 (120–490)

0.019

Total IgE, kU/L

2627 ± 1904

1913 ± 1898

0.063

FVC %pre

81 ± 13

86 ± 17

0.026

FEV1%pre

69 ± 15

76 ± 18

0.004

ACT score

17 ± 5

22 ± 3

0.001

Dose of corticosteroids, mg/d

2.5 (0.6–12)

0.6 (0.5–4)

0.018

Acute exacerbation rate

2 (0.8–3)

0 (0–1)

0.004

Hospitalization rate

1 (0–1)

0 (0–0)

0.016